GSK plc stock (GB0009252882): pipeline updates and legal risks keep the spotlight on the pharma heavyweight

GSK remains in focus after recent pipeline news and ongoing US litigation discussions around heartburn drug Zantac, while investors weigh the company’s vaccines and specialty medicines growth story against legal and patent risks.

GSK plc stays on the radar of global healthcare investors as the group advances its vaccines and specialty medicines pipeline while continuing to navigate high-profile US litigation related to the discontinued heartburn drug Zantac. The combination of scientific progress, steady cash generation and unresolved legal questions keeps the stock in the spotlight for both European and US-focused portfolios, according to company disclosures and recent court filings reported by major financial media in spring 2026.

As of: 22.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: GSK
• Sector/industry: Pharmaceuticals and vaccines
• Headquarters/country: United Kingdom
• Core markets: Europe, United States and international markets
• Key revenue drivers: Vaccines, specialty medicines, HIV treatments
• Home exchange/listing venue: London Stock Exchange (ticker: GSK); secondary listing on NYSE
• Trading currency: GBP in London, USD in New York

GSK plc: core business model

GSK is a global biopharmaceutical company focused on developing and commercializing prescription medicines and vaccines. The group’s strategy emphasizes infectious diseases, HIV, respiratory, immunology and oncology, supported by a research organization that increasingly uses genetics and data-driven approaches to identify new targets. Management positions the company as a focused “biopharma” player following the 2022 spin-off of its consumer healthcare arm into Haleon, which shifted GSK toward higher-margin innovative therapies.

The company’s revenue mix is built around three major pillars: vaccines, specialty medicines and HIV/established pharmaceuticals. Within vaccines, GSK has leading positions in areas such as shingles and meningitis, while its specialty medicines portfolio includes respiratory and immunology treatments that aim to address high unmet medical needs. The HIV business is consolidated in the ViiV Healthcare joint venture, in which GSK holds a majority stake and which contributes meaningful sales and profits, particularly in the US market where HIV therapies command premium pricing.

GSK generates cash flows primarily from patented medicines and vaccines with relatively high gross margins, which help fund research and development spending. The company also benefits from scale in global manufacturing and distribution, enabling it to support large vaccination campaigns in both developed and emerging markets. At the same time, the business is inherently exposed to patent expiries, regulatory scrutiny and pricing pressure from payers, especially in the US where negotiations with large pharmacy benefit managers and government programs can influence profitability.

The spin-off of the consumer health operations has simplified GSK’s structure but also reduced diversification, leaving investors more directly exposed to the ups and downs of the innovative biopharma pipeline. This makes clinical trial milestones, regulatory approvals and safety outcomes key catalysts for the share price. For US investors, the American Depositary Shares listed on the New York Stock Exchange provide direct participation in these dynamics without the need to trade in London or deal in sterling.

Main revenue and product drivers for GSK plc

Vaccines are one of GSK’s most important revenue engines. The shingles vaccine Shingrix has been a flagship product in recent years, particularly in the US where strong demand among older adults has supported significant sales. The product’s performance depends on continued uptake in key age cohorts and on competitive dynamics as rivals target the same indication. In meningitis, GSK offers several vaccines that contribute to a diversified franchise, often included in national immunization programs, which can provide relatively stable, volume-driven revenue streams.

Beyond vaccines, GSK’s specialty medicines portfolio focuses on respiratory and immunology conditions, including asthma and chronic obstructive pulmonary disease. Drugs in this area often face competition from both branded and generic alternatives, pushing the company to innovate with new mechanisms of action and delivery technologies. Successful launches can support higher growth and margins, but the development process is long and expensive, with no guarantee that candidates will pass late-stage trials or secure regulatory approval in the US and other major markets.

The HIV business, largely run through ViiV Healthcare, remains a significant contributor to group earnings. Regimens built around integrase inhibitors have helped the joint venture maintain a strong position in the US and Europe, although competition from other global pharmaceutical groups is intense. Pricing discussions with US payers and the evolution of government coverage programs, including Medicare and Medicaid, can influence the net revenue GSK ultimately realizes, even when headline list prices rise.

In addition to these core areas, GSK markets a range of established pharmaceuticals that, while often slower-growing, can generate reliable cash flows to support investment in the pipeline. However, as patents expire and generic competitors enter the market, revenues from these mature products typically decline. The timing and magnitude of such patent cliffs are an important consideration for investors assessing the sustainability of GSK’s dividend and its capacity to finance R&D and potential business development transactions.

GSK’s legal and regulatory backdrop remains a key focus

One of the most closely watched issues around GSK in recent years has been litigation in the United States related to the heartburn drug Zantac, which contained the active ingredient ranitidine. The medicine was withdrawn from many markets after regulators expressed concerns about potential impurities. Since then, GSK and other former manufacturers have faced thousands of lawsuits alleging links between the product and certain cancers. Court developments and settlements reported by major financial outlets have periodically influenced sentiment toward the stock, especially among US-based investors.

According to publicly available court documents and company statements summarized by international news agencies in 2023 and 2024, GSK has contested allegations that ranitidine causes cancer and has defended its scientific position. Some cases in US federal court have been dismissed, while others at the state level continue, creating a patchwork of outcomes. The company has also announced certain settlements in specific jurisdictions, though it has typically avoided admitting liability. Each new ruling or settlement can lead to reassessments of potential financial exposure, which in turn may affect market perceptions of GSK’s risk profile.

Beyond litigation, GSK operates in a heavily regulated environment in all its key markets. US agencies such as the Food and Drug Administration and the Centers for Disease Control and Prevention play central roles in approving vaccines and medicines, issuing safety communications and influencing vaccination guidelines. Changes in regulatory requirements or safety labeling can alter the commercial outlook for individual products. For vaccines in particular, inclusion in US immunization schedules can significantly boost demand, while any safety concerns can have the opposite effect.

Regulation is equally important in Europe, where the European Medicines Agency and national health authorities evaluate benefit-risk profiles and negotiate reimbursement terms. For a company like GSK, which sells products worldwide, divergent regulatory or pricing decisions between regions can complicate global launch strategies and revenue forecasting. Investors therefore pay attention not only to whether a product is approved, but also to the specifics of its label, the indicated patient population and any post-approval study obligations that may increase ongoing costs.

Research pipeline and strategic priorities

GSK’s long-term growth prospects depend heavily on its late-stage research pipeline, spanning vaccines and therapies for infectious diseases, respiratory conditions, oncology and immunology. Management has emphasized a focus on scientifically validated targets, often based on human genetics or functional genomics, aiming to improve the probability of success in clinical development. The company has also invested in modalities such as monoclonal antibodies and other biologics, which can command strong pricing power if they address clear unmet needs.

Pipeline updates, including trial initiations, interim readouts and final Phase III results, frequently serve as catalysts for the share price. Positive data can raise expectations for future revenue contributions, while setbacks may force the company to write down R&D investments and reconsider portfolio priorities. As with other large pharmaceutical groups, GSK sometimes adjusts its focus by out-licensing assets that are no longer core, or by in-licensing or acquiring promising candidates that complement its existing strengths, particularly in vaccines and infectious diseases.

Strategically, the company has also highlighted efficiency initiatives to improve operating margins. These include streamlining manufacturing networks, using digital tools to optimize clinical trial design and execution, and focusing on markets where it can achieve scale advantages. While such programs can support profitability, they may also involve restructuring charges and changes in workforce allocation, which investors must factor into their assessment of near-term earnings versus long-term competitiveness.

Given GSK’s scale and diversified pipeline, the company’s R&D budget is substantial, and management faces constant decisions about which programs to prioritize. For US-focused investors, particular attention often goes to assets that could become blockbusters in the American market, where pricing remains relatively favorable compared with many other regions. At the same time, increasing scrutiny of drug costs in the US Congress and through new legislation adds an element of policy risk to the longer-term outlook.

Why GSK plc matters for US investors

GSK holds a secondary listing on the New York Stock Exchange, making its shares accessible to US investors in the form of American Depositary Shares traded in US dollars. For investors seeking exposure to global healthcare and vaccine trends, the company offers a diversified portfolio that is not solely tied to the US market but still generates significant revenue there. This combination means that GSK’s performance reflects both US healthcare dynamics and broader international demand for vaccines and specialty medicines.

In the United States, GSK is a key supplier of vaccines used in routine immunization schedules and certain adult vaccination campaigns, including shingles and meningitis. The company also participates in government contracting for public health initiatives, which can provide relatively stable volumes but sometimes at lower unit prices. For US investors, this creates a blend of growth opportunities and policy exposure, as changes in federal and state programs, or in recommendations from advisory committees, may influence volumes and margins.

Additionally, US investors often compare GSK with domestic pharmaceutical peers when considering sector allocation. Factors such as dividend yield, payout policy, balance sheet strength and pipeline depth are typically evaluated against those of large US-based companies. While exact yields and ratios fluctuate with the share price and company decisions, GSK’s commitment to returning cash to shareholders through dividends remains a central element of its equity story, supported by cash flows from established products and vaccines.

Conclusion

GSK plc today represents a focused biopharma group whose prospects hinge on the performance of core vaccine and specialty medicine franchises, the success of a sizeable research pipeline and the resolution of legacy legal matters such as the Zantac litigation in the United States. The company’s spin-off of its consumer health business has sharpened its profile but also increased dependence on fewer, higher-value therapeutic areas that can be affected by clinical, regulatory and competitive outcomes. For US investors, the NYSE listing offers convenient access to a large European-based healthcare name with global reach, meaningful exposure to US drug and vaccine markets and an established record of distributing cash via dividends. Balancing these strengths are the usual sector risks of patent expiries, pricing pressure and policy change, as well as the specific uncertainties associated with ongoing court proceedings, which together form the context in which the stock is evaluated.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.